|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Insight into the associations of MS-associated <i>IL2RA</i> SNPs, as these new findings provide, offers a better understanding of CD25 variation in the immune system and can lead to new insights into how MS-associated SNPs contribute to development of MS.
|
31242590 |
2019 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism (rs1800693) of TNFRSF1A (type 1 tumour necrosis factor receptor) encodes a potentially anti-inflammatory soluble truncated form of the p55 receptor, which is associated with predisposition to multiple sclerosis but protection against ankylosing spondylitis (AS).
|
29535371 |
2019 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
|
31407831 |
2019 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Daclizumab is a humanized monoclonal IgG1 antibody that binds to CD25 that has been studied for the treatment of multiple sclerosis (MS).
|
30885425 |
2019 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis aims to evaluate the relationship of the IL2RA polymorphisms rs2104286 and rs12722489 with MS risk in different populations.
|
29648897 |
2018 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We speculate that vitamin D<sub>3</sub> may promote the maintenance of CD25-related immune homeostasis in MS.
|
29153546 |
2018 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
|
29589548 |
2018 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The gene polymorphisms at the loci of IL2RA rs2104286 and rs12722489 may increase the onset risk of MS. IL2RA-rs2104286 showed a positive relationship with CXCR5-rs3922.
|
30352019 |
2018 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that gene expression in peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs) and MS patients are associated with IL2RA SNP rs2104286 and that gene expression levels correlate with soluble CD25 (sCD25) concentrations - that are affected by rs2104286.
|
28511943 |
2017 |
|
Multiple Sclerosis
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that differential methylation of the IL2RA promoter in T cells could be an important pathogenic mechanism in MS.
|
28077880 |
2017 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56<sup>bright</sup> natural killer cells, which seems to be the leading mechanism of action in MS.
|
28450896 |
2017 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Overexpression of the Cytokine BAFF and Autoimmunity Risk.
|
28445677 |
2017 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
|
26819262 |
2016 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
More importantly, UC-MSC-primed Tregs of MS patients significantly inhibited the proliferation of PHA-stimulated autologous and allogeneic CD4+CD25- T effector cells (Teffs) from MS patients and healthy individuals compared to non-UC-MSC-primed (naïve) Tregs from the same MS patients (p<0.01).
|
27705922 |
2016 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, MS quiescence appears to correlate with restoration of suppressive function in memory-derived CD4(+)CD25(-)FOXP3(-) iTregs.
|
27154631 |
2016 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells.
|
26765264 |
2016 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Both signals in the two variant model for MS affect CD25 expression on distinct subpopulations of CD4+ T cells, which are key cells in the autoimmune process.
|
26106896 |
2015 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Associations of CLEC16A and IL2RA with MS were validated.
|
25903733 |
2015 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
IL2RA variants are known to protect against multiple sclerosis, diabetes mellitus and RA.
|
26350950 |
2015 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The proposed procedure is illustrated on a multiple sclerosis (MS) family data set including genotypes of SNPs in IL2RA, confirming the advantage of using a family design to identify causal variants.
|
25585700 |
2015 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although the possibility that IL2RA is a risk factor for MS development was not confirmed in this Japanese population, IL2RA gene polymorphisms were able to modify the disease activity in female MS patients, but had no influence on either susceptibility or disease phenotype in NMO/NMOSD patients.
|
24332945 |
2014 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, similar to MS, the MGAT1 variant haplotype interacted with CTLA4 (P=0.03), and a combination of IL2RA and IL7RA (P=0.01).
|
24572742 |
2014 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We show that an MS-associated polymorphism in the IL-2 receptor alpha (IL2RA) gene specifically increases the frequency of GM-CSF-producing TH cells.
|
25278028 |
2014 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Further characterization of the effect of IL2RA and IL7R genetic variants in defined MS subtypes is warranted to evaluate the effect of these genes on specific clinical outcomes and to further elucidate the mechanisms of disease onset and progression.
|
24770783 |
2014 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Flow cytometry was used to study the activation of CD4+ T cells and T cell subsets (CD25(high) and CD26(high) cells), monocytes and DCs in a cross-sectional study of 39 untreated and 29 GA-treated MS patients, the latter followed prospectively for one year.
|
22653658 |
2013 |